MYRIAD GENETICS, INC. Proceeds from Issuance of Secured Debt
MYRIAD GENETICS, INC. (MYGN) reported Proceeds from Issuance of Secured Debt of $125.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSecuredDebt · last filed 2026-02-24
- MYRIAD GENETICS, INC. proceeds from issuance of secured debt for the quarter ending 2025-12-31 was $0.00.
- MYRIAD GENETICS, INC. proceeds from issuance of secured debt for the quarter ending 2024-12-31 was $0.00.
- MYRIAD GENETICS, INC. proceeds from issuance of secured debt for fiscal 2025 was $125.00M.
- MYRIAD GENETICS, INC. proceeds from issuance of secured debt for fiscal 2024 was $0.00.
- MYRIAD GENETICS, INC. proceeds from issuance of secured debt for fiscal 2023 was $0.00.
| Period end | Proceeds from Issuance of Secured Debt 3 month | Proceeds from Issuance of Secured Debt 9 month | Proceeds from Issuance of Secured Debt 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $125.00M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $125.00M 10-Q · filed 2025-11-04 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |